Cryo-Cell International, Inc. (CCEL) - Form 8-K Summary
Business Context and Reporting Period
Cryo-Cell International, Inc., a Delaware corporation, filed this Current Report on Form 8-K on October 15, 2024. The filing serves to announce the Company's financial results for the three and nine months ended August 31, 2024. The report incorporates a press release (Exhibit 99.1) by reference but explicitly states that the press release is not "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are detailed in the press release furnished as Exhibit 99.1, which is not included in the input text. Consequently, no specific financial figures can be extracted from this document alone.
Material Changes
The filing does not provide data to compare current period performance against prior comparable periods. Any material changes in financial condition or results of operations are contained within the referenced press release (Exhibit 99.1).
Guidance, Outlook, and Risks
This Form 8-K does not include management commentary, forward-looking guidance, specific risk factors, or details on contingencies. The document notes that the press release may contain hypertext links to the Company's website, but information on the website is not incorporated by reference into this filing.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated October 15, 2024) for specific revenue, net income, and cash flow figures for the periods ended August 31, 2024.
- Verify year-over-year and quarter-over-quarter performance trends in the full press release.
- Check the Company's website for additional context, noting that such information is not legally incorporated into this 8-K filing.
- Confirm the trading symbol (CCEL) and exchange (NYSE American LLC) for accurate market data correlation.